Featured Research

from universities, journals, and other organizations

New anti-HIV gene therapy makes T-cells resistant to HIV infection

Date:
January 26, 2011
Source:
Mary Ann Liebert, Inc., Publishers
Summary:
An innovative genetic strategy for rendering T-cells resistant to HIV infection without affecting their normal growth and activity is described in a new research paper.

An innovative genetic strategy for rendering T-cells resistant to HIV infection without affecting their normal growth and activity is described in a paper published in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc.

Related Articles


A team of researchers from Japan, Korea, and the U.S. developed an anti-HIV gene therapy method in which a bacterial gene called mazF is transferred into CD4+ T-cells. The MazF protein is an enzyme (an mRNA interferase) that destroys gene transcripts, preventing protein synthesis. The design of this mazF gene therapy vector ensures that synthesis of the MazF protein is triggered by HIV infection. When HIV infects treated T lymphocytes, MazF is induced, blocking HIV replication and, essentially, making the T-cells HIV resistant.

This elegant gene therapy tool was developed by Hideto Chono and colleagues from Takara Bio Inc. (Otsu, Shiga, Japan), Seoul National University and ViroMed Co. (Seoul, Korea), National Institute of Biomedical Innovation (Tsukuba, Ibaraki, Japan), and Robert Wood Johnson Medical School (Piscataway, NJ). The authors describe the theory and science behind this strategy in the paper entitled, "Acquisition of HIV-1 Resistance in T Lymphocytes Using an ACA-Specific E. coli mRNA Interferase."

"The potential of using vectors to express genes within a cell to block viral infection was first considered by David Baltimore in a strategy called 'intracellular immunization.' This study illustrates a unique way in which intracellular immunization can be achieved," says James M. Wilson, MD, PhD, Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia.


Story Source:

The above story is based on materials provided by Mary Ann Liebert, Inc., Publishers. Note: Materials may be edited for content and length.


Journal Reference:

  1. Hideto Chono, Kazuya Matsumoto, Hiroshi Tsuda, Naoki Saito, Karim Lee, Sujeong Kim, Hiroaki Shibata, Naohide Ageyama, Keiji Terao, Yasuhiro Yasutomi, Junichi Mineno, Sunyoung Kim, Masayori Inouye, Ikunoshin Kato. Acquisition of HIV-1 Resistance in T Lymphocytes Using an ACA-SpecificE. colimRNA Interferase. Human Gene Therapy, 2011; 22 (1): 35 DOI: 10.1089/hum.2010.001

Cite This Page:

Mary Ann Liebert, Inc., Publishers. "New anti-HIV gene therapy makes T-cells resistant to HIV infection." ScienceDaily. ScienceDaily, 26 January 2011. <www.sciencedaily.com/releases/2011/01/110126121059.htm>.
Mary Ann Liebert, Inc., Publishers. (2011, January 26). New anti-HIV gene therapy makes T-cells resistant to HIV infection. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2011/01/110126121059.htm
Mary Ann Liebert, Inc., Publishers. "New anti-HIV gene therapy makes T-cells resistant to HIV infection." ScienceDaily. www.sciencedaily.com/releases/2011/01/110126121059.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins